Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results
Rhea-AI Summary
Sensei Biotherapeutics (Nasdaq: SNSE) reported third quarter 2025 results and strategic changes on Nov 14, 2025. The board decided to discontinue development of solnerstotug and launched a comprehensive review of strategic alternatives, including asset sales, licensing, collaborations, a sale of the company, merger, or an orderly wind-down.
The company implemented a workforce reduction of approximately 65% and will retain a small team to manage the review, regulatory compliance, and orderly cessation of development activities.
Key financials for the quarter ended Sept 30, 2025: $25.0M cash, cash equivalents and marketable securities (down from $41.3M at Dec 31, 2024); R&D expense $2.5M (vs $4.6M prior year); G&A expense $2.3M (vs $3.2M prior year); net loss $4.6M (vs $7.3M prior year).
Positive
- Cash runway preserved by cost cuts and workforce reduction
- R&D expense declined 46% YoY (from $4.6M to $2.5M)
- Net loss improved 37% YoY (from $7.3M to $4.6M)
Negative
- Cash, equivalents and marketable securities declined 39% since Dec 31, 2024 ($41.3M to $25.0M)
- Workforce reduced by ~65%, materially lowering operational capacity
- Discontinuation of solnerstotug halts a development asset and its future value
News Market Reaction 2 Alerts
On the day this news was published, SNSE declined 11.25%, reflecting a significant negative market reaction. Argus tracked a trough of -2.5% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $10M at that time.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter 2025.
On October 30, 2025, the Company announced that its Board of Directors determined, after extensive consideration of the Company’s development pipeline and current market conditions, to discontinue development of solnerstotug and initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value. The Company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, licensing arrangements, collaborations, a sale of the Company, a business combination, a merger, or an orderly wind-down of operations.
In connection with this strategic review, the Company has implemented a workforce reduction to preserve cash, reducing its workforce by approximately 65 percent. The Company is retaining a small team of employees to assist in exploring strategic alternatives, maintaining compliance with regulatory and financial reporting requirements, and managing the orderly cessation of development activities.
Third Quarter 2025 Financial Results
Cash Position: Cash, cash equivalents and marketable securities were
Research and Development (R&D) Expenses: R&D expenses were
General and Administrative (G&A) Expenses: G&A expenses were
Net Loss: Net loss was
About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead product candidate is solnerstotug, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn.
| Condensed Statements of Operations | |||||||
| (Unaudited, in thousands except share and per share data) | |||||||
| Three Months Ended September 30, | |||||||
| 2025 | 2024 | ||||||
| Operating expenses: | |||||||
| Research and development | $ | 2,536 | $ | 4,637 | |||
| General and administrative | 2,315 | 3,186 | |||||
| Total operating expenses | 4,851 | 7,823 | |||||
| Loss from operations | (4,851 | ) | (7,823 | ) | |||
| Total other income | 282 | 570 | |||||
| Net loss | $ | (4,569 | ) | (7,253 | ) | ||
| Net loss attributable to common stockholders | (4,569 | ) | (7,253 | ) | |||
| Net loss per share, basic and diluted | $ | (3.62 | ) | $ | (5.77 | ) | |
| Weighted-average common shares outstanding, basic and diluted | 1,261,290 | 1,257,299 | |||||
| Selected Condensed Balance Sheet Data | |||||
| (Unaudited, in thousands) | |||||
| September 30, 2025 | December 31, 2024 | ||||
| Cash and cash equivalents | $ | 10,562 | $ | 9,994 | |
| Marketable securities | 14,479 | 31,341 | |||
| Total assets | 27,589 | 45,361 | |||
| Total liabilities | 4,582 | 6,975 | |||
| Total stockholders’ equity | 23,007 | 38,386 | |||
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe”, “designed to,” “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Sensei’s current beliefs and expectations. These forward-looking statements include Sensei’s discontinued development of solnerstotug and review of strategic alternatives aimed at maximizing shareholder value and related workforce reduction. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the risks relating to volatility and uncertainty in the capital markets for biotechnology companies; availability of suitable third parties with which to conduct contemplated strategic alternatives; whether Sensei will be able to pursue a strategic transaction, or whether any transaction, if pursued, will be completed on attractive terms or at all; changes in expected or existing competition; changes in the regulatory environment; and unexpected litigation or other disputes; and other risks and uncertainties that are described in Sensei’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on November 14, 2025 and Sensei’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Sensei as of the date of this release, and Sensei assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor and Media Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com
FAQ
What did Sensei Biotherapeutics (SNSE) announce on Nov 14, 2025 about solnerstotug?
How much cash did Sensei Biotherapeutics (SNSE) report as of Sept 30, 2025?
What workforce change did Sensei Biotherapeutics (SNSE) make in Q3 2025?
How did Sensei Biotherapeutics (SNSE) R&D and G&A expenses change in Q3 2025?
What strategic options is Sensei Biotherapeutics (SNSE) exploring after Oct 30, 2025?
What was Sensei Biotherapeutics (SNSE) net loss in Q3 2025 and how did it compare year-over-year?
